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Abstract
The National Heart, Lung, and Blood Institute convened working group to provide basic and
clinical research recommendations to the National Heart, Lung, and Blood Institute on the
development of an integrated approach for identifying those individuals who are at high risk for
cardiovascular event such as acute coronary syndromes (ACS) or sudden cardiac death in the
“near term.” The working group members defined near-term as occurring within 1 year of the time
of assessment. The participants reviewed current clinical cardiology practices for risk assessment
and state-of-the-science techniques in several areas, including biomarkers, proteomics, genetics,
psychosocial factors, imaging, coagulation, and vascular and myocardial susceptibility. This report
presents highlights of these reviews and a summary of suggested research directions.
Keywords
cardiovascular diseases; death, sudden; myocardial infarction; risk factors; risk prediction
Copyright © 2010 American Heart Association. All rights reserved.
Reprint requests to Kim A. Eagle, MD, University of Michigan Cardiovascular Center, 1500 E Medical Center Dr, Suite 2131, Ann
Arbor, MI, 48109-5852. keagle@umich.edu.
Co-chairs of the Writing Group are Kim A. Eagle, MD, and Sidney C. Smith, Jr, MD.
Guest Editor for this article was Joseph S. Alpert, MD.





Circulation. Author manuscript; available in PMC 2011 March 30.
Published in final edited form as:















The proper deployment of preventive strategies requires an accurate classification system
that allows the physician to target intensive treatments to the highest-risk patients. A
commonly recommended approach is a multivariable assessment such as the Framingham
Risk Score (FRS).1 Although the FRS is recommended in many guidelines on
cardiovascular risk assessment,2 it has some limitations. It does not include several factors
of the metabolic syndrome (glucose intolerance, central obesity, and hypertriglyceridemia),
nor does it include family history. Moreover, the FRS classifies risk over a period of 10
years rather than in the near term (within 1 year). Indeed, no algorithm has been developed
that accurately predicts near-term risk across diverse populations.
The ability to forecast near-term risk of ACS or sudden cardiac death would represent an
important advance in cardiovascular medicine because it would clarify which individuals are
in most urgent need of intervention. It would help identify those rare asymptomatic,
apparently healthy individuals who are in imminent danger of a cardiovascular event yet
ordinarily would not receive therapy at all. In asymptomatic individuals judged to be at
intermediate or high risk by the FRS, determining that they are at increased near-term risk
could result in immediate (and perhaps temporary) intensification of therapy or other
interventions. Among patients with known coronary artery disease and/or some degree of
left ventricular dysfunction, those at high near-term risk would warrant the most aggressive
level of treatment and monitoring.
Post-ACS Risk Prediction
Tools to predict near-term cardiovascular risk after ACS are already available. For example,
for patients presenting with ACS, the 7-point Thrombolysis in Myocardial Infarction (TIMI)
risk score is an easy and valid tool for predicting risk of very-near-term events (eg, 14 to 30
days).3 However, risk stratification developed from randomized trial populations may lack
generalizability to patients seen in usual clinical practice.4 The Global Registry of Acute
Coronary Events (GRACE) risk score has been well validated as a risk prediction tool
applicable for types of ACS patients encountered in clinical practice.4–6 Additionally,
multiple biomarkers have been shown to have prognostic value in the post-ACS setting, both
individually and in combination.7
Many drugs have been proven to reduce near-term, post-ACS events in randomized trials
(eg, angiotensin-converting enzyme inhibitors, aspirin and thienopyridines, supplements,
aldosterone blockers, and statins). In some cases, interventions have been shown to be of
particular value in patients at high short-term risk. For example, some studies have
demonstrated improved post-ACS outcomes with the early intervention strategy compared
with the early conservative strategy in patients presenting with high TIMI risk scores; no
difference was seen among patients with low TIMI risk scores.8 Similarly, enoxaparin
provided improved outcomes compared with unfractionated heparin exclusively in
individuals with high TIMI risk scores.3 Thus, determination of near-term risk can help
guide optimal therapy in post-ACS patients.
Although much work is needed to perfect near-term risk prediction in the post-ACS setting,
there is a relative wealth of information compared with the scant data available for
asymptomatic individuals. A major unmet need is the development of risk scores akin to the
TIMI and GRACE scores to forecast near-term risk in the primary prevention setting.
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Candidate Areas for New Risk Assessment Tools
Classic and Novel Risk Factors
Since the initial 4 risk factors underlying cardiovascular disease (CVD)—hypertension,
hypercholesterolemia, left ventricular hypertrophy, and diabetes mellitus—were described in
1961 by Kannel et al,9 the list has grown to include many others. Additional clinical
cardiovascular risk factors such as male gender, black race, advancing age, smoking,
insufficient exercise, obesity, and family history are well recognized. 10 However, all of
these are fixed or chronic conditions that are better suited to predicting long-term risk than
near-term risk. What are needed are novel risk factors that reflect acute processes
influencing atherosclerotic plaque rupture, atherothrombosis, and electric instability in the
myocardium. Of most value would be novel, easy-to-measure biomarkers that would make it
possible to screen large numbers of individuals for near-term risk.
Biomarkers are proteins or metabolites, individually or in combination, that correlate to
pathological processes.11 A clinically useful biomarker should have specificity to the disease
process; should differ quantitatively from controls, with this difference being larger than
technical and biological variation combined; should be stable in blood or other body fluids;
and should present in sufficient amounts for easy clinical measurement.12
Some novel plasma-based biomarkers are associated with myocardial, renal, skeletal muscle,
and brain involvement from atherosclerotic vascular disease, including brain natriuretic
protein, bone morphogenic protein, transforming growth factor-β, and neuroprotein D1.
These biomarkers may be related to damage of “target organs” and thus are potential risk
factors. However, care must be taken to distinguish those that are truly predictors of future
events from those that are secondary, downstream markers reflecting a prior event and have
no predictive value. For example, the plasma level of troponin, a marker for myocardial
damage, has little prognostic value in the primary prevention setting, where the test is
principally used as a diagnostic marker to determine whether a symptomatic patient has
suffered a cardiovascular event. In the secondary prevention setting, however, troponin has
been demonstrated to be a useful biomarker for determining near-term risk and is a
component of the TIMI risk score.
Other biomarkers are associated with atherosclerosis, inflammation, endothelial cell
dysfunction, plaque instability, thrombosis, and myocardial susceptibility and so are more
likely to be causal risk factors. How these “new” biomarkers and “old” risk factors
interrelate and how they might together help us define near-term risk require more study.
Atherosclerosis and Inflammation Biology
The focus in the field of the pathophysiology of atherosclerosis has shifted from the concept
of a lipid storage disease to that of a chronic inflammatory process. In the first phase,
inflammatory cells such as monocytes join the arterial endothelial and smooth muscle cells
of the normal artery to initiate an inflammatory response. Multiple adhesion molecules for
leukocytes, chemoattractant cytokines, and activators of leukocyte function are operative in
the atherogenic process.
Vascular cell adhesion molecule-1 mediates mononuclear cell adhesion to activated
endothelial cells.13 Bound leukocytes enter the arterial intima in response to chemokines
such as monocyte chemoattractant protein-1.13 Leukocyte activators such as macrophage
colony-stimulating factor promote the maturation of monocytes into macrophage foam cells
and stimulate their elaboration of multiple mediators of the atherosclerosis process.14
Inflammatory mediators also participate in the progression of atherosclerotic disease.
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The ultimate clinical expression of atherosclerotic pathology, atherothrombosis, causes the
most dreaded clinical complications of this disease such as ACS. Inflammation sets the stage
for the thrombotic complications of atherosclerosis not only by affecting the “solid state” of
the lesion but also by hindering fibrinolysis and augmenting thrombosis and coagulability in
the fluid phase of blood.15
The use of biomarkers of inflammation such as vascular cell adhesion molecule-1, monocyte
chemoattractant protein-1, and macrophage colony-stimulating factor in clinical medicine
offers the potential to sharpen our ability to predict cardiovascular risk. Inflammatory
markers relate to prospective risk of cardiovascular complications and show promise to
potentially add relevant prognostic information. However, moving from general measures of
inflammation to more transitory markers that may be associated with greatly heightened
near-term risk requires further study.
The Endothelium
Endothelial cells from arteries and veins display distinct phenotypes. Some of these site-
specific properties are epige-netically predetermined during embryogenesis, whereas others
are mediated by differences in the microenvironment, most notably hemodynamic forces.
Changes in endothelial cells overlying atherosclerotic plaque include irregular orientation
and altered gene/protein expression/activity (including proinflammatory transcription
factors, hemostatic factors, cell adhesion molecules, and nitric oxide).16 Atherosclerosis-
associated endothelium displays abnormalities in vasomotor tone, increased leukocyte
trafficking, and exaggerated apoptosis. Dysfunctional endothelium promotes oxidation of
lipoproteins, inflammation, lipid accumulation, and smooth muscle cell proliferation.
Endothelial dysfunction, assayed by flow studies, measures endothelium-dependent
vasodilation. Abnormalities have been correlated with atherosclerosis and risk for ACS.17,18
However, these studies are highly operator dependent, and they measure only a single
function of the endothelium. An important goal in vascular biology is to develop novel
methods for diagnosing endothelial dysfunction and to use this information to predict plaque
vulnerability. Such a diagnostic platform may ultimately include some combination of
soluble mediators, cell-based assays, and molecular imaging. Dysfunctional endothelial cells
release a number of soluble mediators into the blood, including endothelin-1, von
Willebrand factor, tissue-type plasminogen activator, and soluble thrombomodulin.19
Although few of these biomarkers are truly specific for the endothelium, circulating levels
of one or another marker have been correlated with an increased risk for cardiovascular
events. However, systematic analysis and comparison of available biomarkers are lacking.
Use of multiplex ELISAs and/or proteomics approaches to measure myriad endothelium-
derived soluble mediators simultaneously may yield important diagnostic/prognostic
information that is not available from single mediator assays. Cell-based assays include
quantification and/or phenotyping of circulating endothelial cells, endothelium-derived
microparticles, and endothelial progenitor cells.20–22 Studies have demonstrated an
association between the number of circulating cells or microparticles and coronary artery
disease. The phenotype of cells and/or microparticles (eg, with fluorescence activated cell
sorting) may provide valuable information about the vascular bed of origin and underlying
disease status. The precise role for cell-based assays in diagnosing the vulnerable plaque in
an individual patient remains to be determined.
Finally, molecular imaging holds promise. As an example, phage display has been used to
identify a novel vascular cell adhesion molecule-1–specific cell-internalizing peptide that
allows sensitive magnetic resonance imaging of atherosclerotic lesions in mice.23 It appears
likely that clinical events occur minutes, hours, days, or even weeks after initiation of
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processes that are occurring at the endothelial level. Developing test strategies to identify
these processes before their phenotypic expression has great potential.
Triggers of Plaque Rupture and the Concept of Vulnerable Blood
The probability that an individual will suffer an acute cardiovascular event in the near term
is likely determined both by her/his burden of atherosclerotic plaques at relevant locations
(coronary, carotid, mesenteric, iliofemoral arteries, etc) and by the probability that each
plaque will become disrupted and trigger thrombosis of a magnitude and persistence
sufficient to critically narrow or occlude the vessel or to produce symptomatic emboli.
Knowledge of the indexes of plaque burden, the frequency of plaque disruption in a given
individual, and that individual’s tendency toward thrombosis should together help predict
near-term risk for cardiovascular events.
Assessing the frequency of subclinical plaque disruption might provide a direct and relevant
measure of plaque activity. Plaque erosions and mural thrombi are relatively frequent
incidental findings at autopsy, and plaques often show evidence of repeated rupture and
healing.24 Thus, clinically silent plaque disruption is common. Direct high-resolution
anatomic imaging is 1 approach to detect disrupted plaques; molecular imaging to detect
extracellular matrix proteins or other molecules or cells exposed by plaque disruption is
another.
Platelets and the coagulation cascade have evolved so that they continuously interrogate
vascular integrity. Autopsy and other studies suggest that platelets and fibrin are regularly
incorporated into disrupted atheroma.25 Imaging methods to visualize accumulation/
incorporation of platelets and fibrin at sites of plaque disruption should be developed. An
ability to follow platelet and fibrin accumulation acutely at sites of plaque disruption in vivo
may be valuable for assessing risk of coronary exclusion and potentially for assessing
interventions aimed at plaque stabilization.
Tissues supplied by arteries in which plaque disruptions occur are reporters of plaque
activity, as is evident from transient ischemic attacks. It is conceivable that clinically silent
plaque rupture could leave subtle signatures that might be detected. Approaches might
include sensitive assays of brain- and heart-specific biomarkers that enter the circulation as a
result of “microscopic” ischemia or infarcts or functional tests that reflect subtle alteration in
function (exercise testing, heart rate variability/recovery, T-wave alternans). Such indexes of
subclinical thromboembolic events in the coronary circulation offer potential to predict near-
term risk of ACS.
Whether a given plaque disruption remains silent or gives rise to a symptomatic thrombus
depends on both local (plaque and vessel geometry and the exact composition of what is
exposed to blood) and systemic (platelet, endothelial, monocyte, and coagulation cascade)
function. We need a better understanding of the molecular mechanisms by which plaque
rupture causes thrombosis to develop sensitive assays to measure the likelihood of clinically
important clot formation. Thus, future biomarker studies should include a focus on platelets
and coagulation proteins.
Myocardial Susceptibility
The observation that the clinical outcome of a given myocardial insult may be worse in
certain individuals is called “susceptible myocardium,” defined as myocardium altered so
that the patient is at risk for near-term adverse events (eg, myocardial injury, infarction,
heart failure, or arrhythmias). Susceptible myocardium may be associated with conditions
resulting in altered myocardial function or structure (eg, ischemia, scarring, hypertrophy,
infiltration, inflammation), altered sympathetic nervous system activity (eg, hyperactivity,
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impaired reactivity), severe left ventricular outflow obstruction (eg, aortic stenosis,
hypertrophic obstructive cardiomyopathy), selected electrophysiological disorders (eg,
prolonged QT syndromes), and commotio cordis.26
At least half of the cases presenting with death or first myocardial infarction arise among
subjects without known CVD. We know little about how to identify subjects without known
CVD who may be at risk for susceptible myocardium and thus may be at high risk for near-
term events. Although the conditions associated with susceptible myocardium summarized
above may be identified with imaging and/or physiological testing, these tests are costly and
impractical to apply to the asymptomatic population.
Early after acute ischemic injury, metabolic and/or inflammatory alterations of both
myocytes and microvessels may predict early adverse outcomes, including ischemic events
of greater severity.27–32 New developments related to myocardial susceptibility include
abnormalities in myocardial metabolism (eg, high-energy phosphate depletion), impaired
flow in nonculprit arteries, and immunomediated ischemia-independent widespread
coronary microvessel and/or myocardial inflammation with infarct-related artery patency.33
In a sense, the myocardium may record or store signals (eg, metabolic,34,35 electric,36 or
mechanical37) from subclinical events (eg, ischemia and necrosis) that may predict near-
term clinical events. Further studies of individuals with past ischemic events could yield
important clues for identifying mechanisms and detection algorithms that may be applied to
subjects without known disease.
Environmental Triggers
Studies abound demonstrating that environmental triggers predict an initial cardiovascular
event in the near term.38–40 Triggers include external stimuli (eg, natural disasters, air
pollution, Mondays, morning rising, or ambient temperature), patient behavior (eg, cocaine
use, intake of a high-saturated-fat meal, or atypically intense physical activity), and patient
emotional reactions (extreme anger or anxiety).38,40
In a study of triggers for acute myocardial infarction,41 heavy exertion was reported to
precipitate 6% of the acute myocardial infarctions, with moderate physical activity being a
precipitant in 29% of the myocardial infarction cases. Intense emotional stress immediately
preceded myocardial infarction in ≈7% of cases and eating in 8% of cases. More than 20%
of the cases in these population-based studies occurred during sleep. Physical exertion
(particularly in the poorly conditioned), emotional stress, anger, and extreme excitement all
appear to act as triggers for an ACS40 by increasing sympathetic tone and catecholamine
release.38 Studies of biomarkers and other readouts that reflect physiological responses to
exercise, feeding, extreme emotion, and other external stimuli may yield clues as to who
may be more susceptible to environmental triggers in the near term and how to protect
against cardiovascular events in these individuals.
Psychosocial Factors
Long-term psychosocial factors such as depression, anxiety, phobic symptoms, low
socioeconomic status, work stress, and the absence of social support have been identified as
independent risk factors in the prediction of first cardiovascular events.39 However, the
majority of long-term psychosocial ACS risk factors have not been tested for their ability to
predict an ACS in the near term. Furthermore, long-term psychosocial factors that may be
implicated in the development of CVD may be quantitatively or even qualitatively different
from those psychosocial factors and triggers that identify a patient at imminent risk for an
ACS.42 Although tests exist to assess an individual’s short-term psychological state such as
the State Trait Anxiety Inventory,43 they have not yet been widely applied to the study of
Eagle et al. Page 6













CVD, and it remains to be seen whether they might provide a means for discriminating
patients at near-term risk.
New Technologies
Noninvasive Imaging Tests
The imaging tests most commonly used to assess prognosis are 99mTc-sestamibi or
thallium-201 stress single-photon emission computed tomography perfusion scans and stress
echocardiography. Numerous studies have shown that stress imaging confers added
predictive value over Duke treadmill scores for the diagnosis of coronary artery disease,44
and coronary artery calcium scores have been shown to more accurately predict coronary
event rates than FRS alone in intermediate-risk individuals.45 However, to date, none of
these tests have been shown to reliably predict events over a short interval of 1 year. Stress
imaging identifies chronic abnormalities of coronary perfusion resulting from
hemodynamically significant lesions and possibly the effect of impaired endothelial function
but not the vulnerability of plaques most likely to trigger acute coronary events.
Coronary computed tomography angiography with the latest-technology scanners appears
promising in diagnosing the presence of significant stenoses. However, approximately two
thirds of myocardial infarctions arise from plaque rupture in coronary artery segments that
previously had <50% stenosis.46 Some measure of total plaque volume may be more helpful
in predicting such events. It has been demonstrated that computed tomography angiography
correlates well with intravascular ultrasonography for measuring coronary artery plaque
area.47 However, systematic longitudinal studies linking the extent of plaque and plaque
morphology, as assessed by computed tomography angiography, with acute events are not
yet available.
Plaques that ultimately rupture or erode, with superimposed thrombosis leading to ACS and
other ischemic events, often do not limit flow, and current techniques cannot yet distinguish
plaques that will remain silent from those that will trigger thrombosis and clinical events.
Advances in anatomic imaging technologies may eventually allow an assessment of plaque
architecture and composition. Future functional imaging approaches that assess, for
example, the activities of plaque macrophages may also help identify plaques likely to
trigger clinical events. More detailed studies of the mechanisms of plaque disruption and the
cellular and biochemical events associated with this process are needed.
There has been progress in the development of new magnetic resonance imaging contrast
agents that target various aspects of atherosclerosis and thrombosis.48 They have potential to
identify the vulnerable plaque, but their diagnostic accuracy and prognostic accuracy have
not yet been established. New imaging approaches such as in vivo 2-photon microscopy49–
51 are being developed to provide new cell-level information on disease processes that
should provide a whole new perspective on the remodeling of the vascular wall in vivo
rather than inference from pathology, genomics, proteomics, or cell culture approaches.
Genomics
The commonly assessed cardiovascular risk factors—lipid profile, hypertension, diabetes
mellitus, homocysteine, lipoprotein (a), body mass index, small dense low-density
lipoprotein particles, and fibrinogen level—are all inherited to some degree. Human genetics
studies are now focusing on identifying sites in the genome, or loci, with variations
associated with each of these quantitative factors. The list of loci implicated in these
phenotypes and, by extension, for cardiovascular end points is growing.
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Until recently, most studies of genetic predictors of vascular disease were largely
unsuccessful because they considered too few candidate loci and/or too few functional
variants in each locus. This has changed dramatically with the completion of the Human
Genome Project, the continuing efforts of the International HapMap Project, and the
availability of resources for deep sequencing of candidate genomic loci in large numbers of
individuals.
The latest studies attempt to consider all common variations in the loci of interest through
dense genotyping of single-nucleotide polymorphisms, consideration of all common
haplotypes (sets of physically linked polymorphisms), or selection of representative single-
nucleotide polymorphisms that act as proxies for all polymorphisms in a locus. Because the
population impact of a disease-associated single-nucleotide polymorphism is a function of
both the magnitude of the effect size and the frequency of the single-nucleotide
polymorphisms, attention has initially focused on common variants. Whole-genome
association studies, with ≥500 000 single-nucleotide polymorphisms tested across the
genome, are underway; however, these studies represent a starting point, with identification
of a list of candidate loci, that then requires more conventional functional studies of the
genes in or near the implicated loci.
Although it is intuitive that a genetic “chip” summarizing genotype data at many risk alleles
may improve prediction of cardiovascular risk, it remains to be demonstrated that genetic
studies will be useful for this purpose. Prior investigations have succeeded in finding highly
penetrant, mendelian rare genetic variants that result in familial dyslipidemia disorders that
cause premature CVD (eg, LDLR, APOB, PCSK9) or result in electrophysiological
syndromes that predispose to sudden death (eg, KCNQ1, KCNQ1, KCNH2, SCN5A, KCNE1,
ANK2, KCNE2, and KCNJ2 for long-QT syndrome; KCNH2 and KCNQ1 for short-QT
syndrome; SCN5A for Brugada syndrome; PRKAG2 for Wolff-Parkinson-White syndrome).
52,53 The more recent whole-genome association studies have identified common genetic
variants that are associated with modestly increased cardiovascular risk (eg, chromosome
9p21 locus),54,55 although the responsible genes remain to be identified. These common
variants may explain much of the inherited basis of CVD and sudden death.
Although knowledge of these DNA variants may eventually be useful in improving risk
prediction algorithms, they will most likely be relevant to predicting lifetime cardiovascular
risk because the variants do not change over time and represent genetic “exposures” to
which a given individual has been subjected while in utero; through infancy, childhood, and
adolescence; and into adulthood. Thus, the variants themselves are unlikely to meaningfully
predict risk in the time frame of months to years. However, an individual’s set of genetic
variants may provide the milieu on which other risk factors may confer increased near-term
cardiovascular risk. For example, an individual with a particular variant of a QT syndrome
gene may have normal risk of ventricular arrhythmia at baseline but may be at severe risk of
arrhythmia if given a QT-prolonging drug, whereas the same drug would promote little risk
in a normal individual. As so-called “pharmacogenomic” information becomes available,
there may be utility to its inclusion into near-term risk algorithms.
Proteomics
Proteomics is the study of the proteome or the protein complement of a sample comprising
all or part (subproteome) of cells, tissue, or a body fluid such as serum or plasma. Although
proteomic analysis can provide insights into the molecular mechanisms of disease at the
protein level, it also has the potential to identify specific disease biomarkers.
The 2 proteomic strategies for biomarker discovery include a broad-based “direct” approach,
in which proteomic techniques are used to screen large numbers of proteins directly in
Eagle et al. Page 8













serum or plasma to identify those that correlate to a disease phenotype, and the candidate
“indirect” biomarker approach, in which proteins are preselected on the basis of known
biological assumptions or from prior discovery. Either way, all biomarkers must be
validated, most often with immunobased assays on a series of large independent cohorts.
This validation phase is critical in the cardiovascular system, in which biomarker
identification is complicated by the fact that heart function is influenced by and influences
many other organ systems, making identification of robust markers difficult without an
understanding of this interplay. Hence, it is important to identify and eliminate biomarkers
that are generic “illness markers” or that overlap with other potentially confounding disease
origins (eg, diabetes mellitus).
In contrast to DNA variants, protein expression and activity in cells, tissue, and body fluids
can be quite mutable over time, with fluctuations over time intervals as brief as minutes.
Thus, it is more plausible for variations with proteins to be causative and predictive of near-
term cardiovascular risk than variations in DNA. As such, proteomics approaches are much
more likely than genomics approaches to identify novel factors that will improve near-term
risk prediction algorithms.
Gene Expression Studies
Although the genetic information encoded in the genome is stable and, for the most part,
does not change over an individual’s lifetime, expression of the roughly 25 000 genes at the
RNA level is highly variable and, like proteins, can readily reflect short-term physiological
changes. Although it is not practical to obtain samples of most tissues to measure gene
expression profiles, easily accessed cells may permit large clinical studies. For example,
data from other fields of medicine suggest that gene expression data from whole blood or
isolated mononuclear cells may have significant predictive power.56 Blood gene expression
profiling can classify individuals with atherosclerosis, heart failure, and early allograft
rejection after cardiac transplantation.57–59 Thus, gene expression analyses may offer a
whole new class of biomarkers for use in near-term risk prediction and is an important area
for future investigation.
Integrative Approaches to Predict Risk
Coronary artery disease is a complex phenotype arising from the interplay of inherited
genetic variants, fluctuations in protein expression and activity, and environmental
exposures. Thus, individuals with coronary artery disease will likely have differing
molecular manifestations of their disease despite having similar clinical phenotypes of
atherosclerotic plaque and/or myocardial infarction. It is conceivable that future research on
inflammation, endothelium, thrombosis, myocardium, environmental triggers, and
psychosocial factors; imaging tests; and studies on genomics, proteomics, and gene
expression will help unravel the complexity of coronary artery disease sufficiently to
provide information on the risk of events for an individual patient and ideally to guide more
precise and targeted therapies ultimately aimed at the individual.
There is a critical need to refine predictive models or to develop them de novo to predict
events in the near term (ie, within a year or so). As described above, biomarker approaches,
possibly supplemented by imaging and genomic analyses, are most likely to be relevant to
near-term cardiovascular risk prediction, and future research should focus there. Because
blood-based constituents are dynamic and can participate in atherosclerosis, the
development of vulnerable plaques, and plaque rupture, a blood-based profile should yield
significant predictive information for near-term events,60 provided that data sets are
collected that consist of clinical data, events, and outcomes of ACS, along with serum
samples that can be used for proteomic and gene expression analyses.
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To fully realize the clinical potential of these diverse sources of information requires a
fundamental change in the way complex, large-scale data are viewed, analyzed, and used.61
Today, the tradition of identifying 1 or a small number of biomarkers continues in the
context of cardiovascular risk, but the 1-gene- or 1-protein-at-a-time approach to risk
prediction is fraught with inefficiency and bias. This working group recognizes the
paramount need for comprehensive, integrative methods of analysis that evaluate relevant
biological pathway information and other factors and that fairly assess the combined
prognostic implications of these data to refine near-term risk assessment and ultimately
guide therapies.
Recommendations for Scientific Investment
The working group recommends the following to develop an algorithm to assess “near-
term” (within 1 year) risk:
• Establish adequately powered population cohorts for time-series studies in
asymptomatic patients who are expected to have higher event rates than the general
population compared with normal control subjects. Obtain comprehensive clinical
and biological information, including cells, tissue, and body fluids, when feasible.
• Use these cohorts to develop novel biomarkers for the “high-risk patient” using
large-scale “omics” technologies (eg, proteomics, gene expression studies) and
other measures (eg, endothelial cell– based markers) as risk reporters. There is a
need for the establishment of the early kinetics of these markers, their validation in
the clinical setting, the development of informatics platforms, and prediction
modeling. Unlike in traditional studies, this will require frequent monitoring of
these biological “signatures,” at least annually, to discern which markers are
perturbed before a clinical event and thus will be specifically useful for predicting
near-term risk.
• Using the “high-risk patient” biomarker profiles, develop novel molecular imaging
strategies for near-term risk prediction in these selected populations.
• Use molecular information from cohort studies to better understand the underlying
pathogenic mechanisms, to discover reporters for those mechanisms, and to better
understand both the environmental and biological determinants that may account
for individual differences in plaque disruption, thrombus formation and
propagation, and triggering mechanisms for acute cardiovascular events.
• Develop novel methods for data analysis and statistical and predictive modeling
using multidimensional data sets.
• Develop and validate a “near-term Framingham score” that may include novel
genetic, proteomic, and imaging markers, as well as environmental variables such
as psychosocial factors. The scoring system should allow the addition of new
variables as they become available. It would be used as a targeted screening tool for
individuals deemed to be at intermediate or high 10-year cardiovascular risk by
traditional risk scores such as the FRS to determine who would benefit from more
intensive monitoring and therapeutic interventions in the near term.
• Develop programs to understand the barriers to the clinical implementation of such
a risk assessment tool. Develop physician education and fellowship training
incentives to encourage clinical acceptance and use of novel risk assessment
methods.
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The Working Group meetings were underwritten by the National Heart, Lung, and Blood Institute at the National
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